FDA denies request to block generic painkiller

In a surprise move, federal health regulators have denied a request by Endo Health Solutions to block generic versions of its painkiller Opana ER, which the company argued can be more easily abused than its branded product.

Endo's Opana ER is a long-acting narcotic used to treat moderate and . Such medications are frequently crushed and then injected or snorted by drug abusers to achieve a euphoric effect.

Last year, Endo reformulated Opana with the aim of making the pills more difficult to crush. The company also hoped the move would protect its expiring patent on Opana by blocking approval of based on the original formulation.

But the FDA said late Friday that it denied the petition, pointing out that Endo's reformulated drug can still be abused.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA: Novartis recall may also affect painkillers

Jan 09, 2012

(AP) -- The Food and Drug Administration is warning patients about a potential mix-up between powerful prescription pain drugs and common over-the-counter medications like Excedrin and Gas-X made at a Novartis manufacturing ...

Recommended for you

FDA proposes accelerated medical device approval plan

12 hours ago

(HealthDay)—The U.S. Food and Drug Administration has proposed a new program that would provide expedited access to high-risk medical devices intended for patients with serious conditions whose medical ...

Targeting drugs to reduce side effects

18 hours ago

(Medical Xpress)—Consider ice cream – the base of which is frozen cream. Ingredients are then added to make different flavours. All these flavours are distinctly different but are created from the same foundation.

User comments